AMENDMENT NO.1 TO BUSINESS COMBINATION AGREEMENTBusiness Combination Agreement • June 8th, 2020 • Immatics B.V. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1, dated as of June 7, 2020 (this “Amendment”), to the BUSINESS COMBINATION AGREEMENT (the “Business Combination Agreement”), dated as of March 17, 2020, by and among Immatics B.V., a Netherlands private limited liability company (“TopCo”), Immatics Biotechnologies GmbH, a German limited liability company (the “Company”), ARYA Sciences Acquisition Corp., a Cayman Islands exempted company (“ARYA”), Immatics Merger Sub 1, a Cayman Islands exempted company and Immatics Merger Sub 2, a Cayman Islands exempted company. TopCo, the Company, ARYA and the Merger Subs, shall be referred to herein from time to time collectively as the “Parties”. Unless otherwise defined herein, capitalized terms are used herein as defined in the Business Combination Agreement.
